Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) — Tangible Net Worth Ratio
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has a Tangible Net Worth Ratio of 97.1% as of December 2025. This metric is calculated by deducting intangible assets (CN¥60.87 Million) from net assets (CN¥2.12 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Shanghai Fudan-Zhangjiang Bio-Pharmaceut book value and equity for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Tangible Net Worth Ratio (2005–2025)
This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 21 annual periods from 2005 to 2025. As of December 2025, the ratio stands at 97.1%, reflecting net assets of CN¥2.12 Billion with intangible assets of CN¥60.87 Million CNY. Also explore net asset momentum of Shanghai Fudan-Zhangjiang Bio-Pharmaceut to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025, covering 21 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 97.1% | CN¥2.12 Billion | CN¥60.87 Million | CN¥2.39 Billion | ▲ +0.1 pp |
| 2024 | 97.0% | CN¥2.31 Billion | CN¥68.65 Million | CN¥2.59 Billion | ▲ +0.7 pp |
| 2023 | 96.3% | CN¥2.36 Billion | CN¥86.35 Million | CN¥2.88 Billion | ▲ +0.7 pp |
| 2022 | 95.7% | CN¥2.25 Billion | CN¥97.15 Million | CN¥2.98 Billion | ▲ +1.0 pp |
| 2021 | 94.7% | CN¥2.19 Billion | CN¥116.47 Million | CN¥2.78 Billion | ▼ -1.0 pp |
| 2020 | 95.7% | CN¥2.01 Billion | CN¥86.85 Million | CN¥2.50 Billion | ▲ +3.8 pp |
| 2019 | 91.9% | CN¥933.15 Million | CN¥75.43 Million | CN¥1.56 Billion | ▼ -6.9 pp |
| 2018 | 98.8% | CN¥993.28 Million | CN¥11.99 Million | CN¥1.46 Billion | ▲ +0.4 pp |
| 2017 | 98.4% | CN¥892.48 Million | CN¥13.93 Million | CN¥1.15 Billion | ▼ -0.4 pp |
| 2016 | 98.9% | CN¥873.05 Million | CN¥9.74 Million | CN¥1.12 Billion | ▲ +0.2 pp |
| 2015 | 98.6% | CN¥765.84 Million | CN¥10.37 Million | CN¥1.02 Billion | ▼ -0.9 pp |
| 2014 | 99.6% | CN¥676.42 Million | CN¥2.87 Million | CN¥824.48 Million | ▼ -0.1 pp |
| 2013 | 99.6% | CN¥565.92 Million | CN¥2.10 Million | CN¥749.22 Million | ▲ +0.3 pp |
| 2012 | 99.4% | CN¥260.11 Million | CN¥1.65 Million | CN¥537.30 Million | ▼ -0.6 pp |
| 2011 | 100.0% | CN¥201.07 Million | CN¥77.00K | CN¥358.88 Million | ▲ +0.0 pp |
| 2010 | 99.9% | CN¥168.71 Million | CN¥95.00K | CN¥304.15 Million | ▲ +0.0 pp |
| 2009 | 99.9% | CN¥168.37 Million | CN¥110.00K | CN¥298.83 Million | ▲ +0.3 pp |
| 2008 | 99.7% | CN¥75.88 Million | CN¥246.00K | CN¥158.45 Million | ▲ +1.1 pp |
| 2007 | 98.6% | CN¥71.04 Million | CN¥1.01 Million | CN¥130.38 Million | ▲ +6.5 pp |
| 2006 | 92.0% | CN¥101.70 Million | CN¥8.10 Million | CN¥145.02 Million | ▼ -5.0 pp |
| 2005 | 97.0% | CN¥123.73 Million | CN¥3.69 Million | CN¥142.91 Million | — |